Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS
Authors:
- Ines GanaIGInes Gana
- Bénédicte DuretzBDBénédicte Duretz
- Anne HulinAHAnne Hulin
- 1 May 2013
- journal article
- research article
- Published by Elsevier in Journal of Chromatography B
- Vol. 926, 83-91
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A TrialJournal of Clinical Oncology, 2009
- Flying under the radar: the new wave of BCR–ABL inhibitorsNature Reviews Drug Discovery, 2007
- Nilotinib therapy in chronic myelogenous leukemiaDrugs of Today, 2007
- Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent DevelopmentsAnnals of Surgical Oncology, 2006
- The development of imatinib as a therapeutic agent for chronic myeloid leukemiaBlood, 2005
- Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single centerCancer, 2005
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001